Malik Fady Ibraham

Malik Fady Ibraham, EVP of Research & Development, has been a consistent seller of stock in 2026, with Form 4 filings showing 54 total transactions across two companies and zero open-market purchases. His recent activity is concentrated entirely in Cytokinetics (CYTK), where he executed 11 open-market sales between March and July 2026 totaling roughly $2.9 million. The largest single disposition came on March 17, when he sold shares worth $474,577, followed by a $273,274 sale the same day. Subsequent sales were smaller but steady, ranging from $64,750 on April 7 to $303,170 on July 7, with the most recent sale of $282,065 occurring on July 21. The pattern is a textbook exercise-and-sell structure: each sale is paired with an option exercise (code M) of identical value, typically $27,300, indicating Ibraham is converting vested options into shares and immediately liquidating them. This mechanical approach—selling the same day as exercise—suggests a cash-generation strategy rather than a directional bet on the stock. Notably, he has not made a single open-market purchase (code P) in the filing period, and his total sell value across all holdings reached $4.38 million, with zero buy value. Ibraham also holds a position in Rocket Pharmaceuticals (RCKT), but his only recent activity there was a June 18 grant of restricted stock (code A) valued at $0—a compensation event, not a discretionary trade. Across both tickers, the absence of any buying conviction, combined with the regular, scheduled nature of the CYTK sales, points to an executive systematically monetizing equity compensation rather than reacting to company-specific news. The filings contain no indication of motive, and the transactions are consistent with routine portfolio management by a senior R&D officer.